Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 315.94M P/E 19.64 EPS this Y -250.00% Ern Qtrly Grth -
Income -4.89M Forward P/E -32.35 EPS next Y -450.00% 50D Avg Chg -12.00%
Sales 177.6M PEG -2.58 EPS past 5Y -17.19% 200D Avg Chg -26.00%
Dividend N/A Price/Book 0.59 EPS next 5Y 36.10% 52W High Chg -50.00%
Recommedations 2.00 Quick Ratio 4.62 Shares Outstanding 58.20M 52W Low Chg -
Insider Own 2.99% ROA -2.43% Shares Float 52.25M Beta 0.71
Inst Own 86.08% ROE -0.91% Shares Shorted/Prior 2.30M/2.49M Price 5.50
Gross Margin 92.42% Profit Margin -2.75% Avg. Volume 586,569 Target Price 5.21
Oper. Margin -19.46% Earnings Date Jul 25 Volume 622,323 Change -2.48%
About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Inc. News
05/16/24 Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
05/16/24 Vanda Pharmaceuticals reports positive data from motion sickness trial
05/15/24 Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
05/10/24 Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
05/09/24 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript
05/09/24 Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
05/09/24 Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
05/08/24 Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
05/07/24 Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
05/07/24 UPDATE 3-Future Pak sweetens take-private offer for Vanda Pharmaceuticals
04/30/24 Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
04/25/24 UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
04/25/24 Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
04/24/24 Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
04/24/24 Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
04/22/24 Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
04/22/24 UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
04/22/24 U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
12:06 PM Butler Hall Capital urges Vanda to engage in sales discussions
04/18/24 Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
VNDA Chatroom

User Image MLBiotechAnalyst Posted - 1 day ago

$VNDA good to see Tang upped his position to 3%. This is right in his wheelhouse…he has already acquired a couple of these types of companies.

User Image Monopoly00 Posted - 1 day ago

$VNDA what’s the bear case here?

User Image Maiquyen003 Posted - 1 day ago

$VNDA $10 next week!

User Image BitNautical Posted - 1 day ago

$VNDA so how was the meetin?

User Image TheBiotechInvestor_ Posted - 1 day ago

$VNDA $SAVA $MDGL Please consider subscribing, It helps me tremendously, and I look forward to continuing to cover biotech stocks. https://youtube.com/@thebiotechinvestor-mq9b?si=0f1N0VJTqLs1LqCx

User Image MLBiotechAnalyst Posted - 2 days ago

$VNDA shareholders voted against the non-CEO board member at the annual meeting. She should be out and the rest of the Board should see it as a mandate to start the sale process with Jeffries. Hey remaining Board members do the right thing and perform your fiduciary duty to shareholders.

User Image Unicorn2020 Posted - 2 days ago

$VNDA I voted yesterday against the CEO and appointed director, no bonus, compensation for them either as the stock has been going down from $22 to $3.30. They deserve nothing. Without the public offer from Future Pak, the stock would have been still in the $3.30-$4.30 range. Anyone compliments these incompetent heads deserve to be blocked for being either blind or stupid.

User Image simonig1 Posted - 2 days ago

$VNDA Biomatch, The "bipolar expansion" you refer to has not yet been launched. In the previous earnings call VNDA said it will be launched in Q3 (next quarter). This management is experienced and methodical!!

User Image Biomatch Posted - 2 days ago

$VNDA According to IQVIA script data the bipolar expansion is not going well. Management needs to be changed today. It all starts with replacing the board members.

User Image jacckkmm Posted - 2 days ago

$VNDA Shares of Vanda Pharmaceuticals Inc. VNDA were up 4.5% on May 15 after the company announced positive data from a second phase III study, which evaluated its neurokinin-1 receptor antagonist, tradipitant for preventing vomiting induced by motion sickness.

User Image Maiquyen003 Posted - 2 days ago

$AKBA $alt $vnda I know this would sound rediculous and self serving, but I am going to say it anyways: I have triggered at least 5 runs for ALT and been responsible for 5 drops for AKBA. I know this from my own trading actions and the immediate reactions of these stocks. I havent figures VNDA out yet since I executed less than 100 trades. It is the cheapest stock in the entire planet now with 3 approved drugs (1 more expected in September), $400m in cash ($7 per share), buyout offer at $7.75 plus $4.37 in cvr (offfer not accepted yet by board).

User Image onemillion2012 Posted - 2 days ago

$HOLO back again at $2.05 only 1100 shares. Come my friends from $asmb $nktr $vnda and make some Cash for the weekend.

User Image MLBiotechAnalyst Posted - 2 days ago

$VNDA it’s time for management and the Board to do the right thing for shareholders: begin a process to sell the company. Use your relationship with Jeffries to get top dollar but don’t keep destroying value as an entrenched board and management.

User Image MLBiotechAnalyst Posted - 2 days ago

$VNDA please vote against the two board members up for reelection to send a message that we will not tolerate the lack of independence of the board and its entrenchment. Also vote against the CEO’s ridiculous compensation.

User Image Maiquyen003 Posted - 2 days ago

$AKBA Im not going anywhere. Holding hard as fuck! Enjoying my smooth and easy ride at $vnda at the moment.

User Image Bornjever Posted - 2 days ago

$AKBA $ALT $VNDA yes on same page and more as I have done ok on bios but you have to use stop loss because I lost money on some stage one or two recently and they failed completely from 3 dollars to .35 and luckily it was only 50 shares of each but I never thought about them both failing in same week. I keep early stage position small until I understand strength and weakness.

User Image HappyTrader2022 Posted - 2 days ago

$VNDA slowly moving towards $7,75

User Image Rounderssss4 Posted - 2 days ago

$VNDA

User Image Unicorn2020 Posted - 2 days ago

$VNDA Set SELL @ $25 my 100K shares GTC. yesterday so no one can borrow it. Beautiful.

User Image Maiquyen003 Posted - 2 days ago

$VNDA I am sensing a breakout here soon! $ALT $akba

User Image Dusan35vidmar Posted - 2 days ago

$VNDA 41000 i hold and bay more

User Image HorizonBull Posted - 3 days ago

$VNDA loaded 2k more

User Image DataJim Posted - 3 days ago

$VNDA I am curious to hear how people are voting and reasons why.

User Image Rounderssss4 Posted - 3 days ago

$VNDA This should be up nice today and tomorrow, continued follow through with yesterday's news. Imo

User Image Maiquyen003 Posted - 3 days ago

$VNDA upcoming shareholder meeting link: https://east.virtualshareholdermeeting.com/vsm/web?pvskey=VNDA2024

User Image Aigner_Andreas Posted - 3 days ago

#GoldenCross $VNDA at 5.36 R12 HiLo 60% T1Y 11 hold DIV N/A #Vanda Phar #stocks #trading #finance #market

User Image Maiquyen003 Posted - 3 days ago

$VNDA there is very little activity on this board since the stock is more than 90% owned by tutes. They should drive it up 500% and park it there.

User Image Trendrebel Posted - 3 days ago

$VNDA Shareholders meeting friday. Interesting to hear if they will announce anything acc. to the offer from Future Pak

User Image Bornjever Posted - 3 days ago

$AKBA $VNDA yes and IOVA much better stock but need time for profit to show and also more drugs get approved and the stock price will explode. So if you see chance to buy 9.00 IOVA it will pay off.

User Image Maiquyen003 Posted - 3 days ago

$VNDA this is worth at least $15 a share. $akba is being played, buy all you can!

Analyst Ratings
Jefferies Hold Feb 25, 22
B of A Securities Buy May 12, 21
Citigroup Neutral Jan 14, 21
Citigroup Buy Oct 29, 20
Citigroup Neutral Jun 9, 20
Citigroup Buy Mar 12, 20
Stifel Hold Feb 26, 20
JMP Securities Market Outperform Feb 26, 20
Citigroup Buy Aug 1, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Aug 21 Sell 5.84 3,724 21,748 113,816 08/23/23
Polymeropoulos Mihael Hristos President and CEO President and CEO Dec 05 Option 3.12 150,000 468,000 1,455,116 12/07/22
Polymeropoulos Mihael Hristos President and CEO President and CEO Dec 05 Sell 10.62 95,900 1,018,458 1,406,866 12/07/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Dec 06 Option 3.12 7,500 23,400 124,952 12/07/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Dec 06 Sell 10.61 4,792 50,843 120,160 12/07/22
Birznieks Gunther SVP, Business Develo.. SVP, Business Development Aug 26 Option 3.12 1,250 3,900 190,057 08/29/22
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Aug 22 Sell 10.2656 3,605 37,007 96,673 08/23/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Jul 28 Sell 10.97 2,239 24,562 117,452 08/01/22
Mitchell Stephen Ray Director Director Jun 13 Sell 9.4789 2,700 25,593 6,515 06/14/22
Williams Timothy SVP & General Counse.. SVP & General Counsel Feb 28 Sell 11.09 12,060 133,745 103,851 03/02/22
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Feb 28 Sell 11.19 6,974 78,039 100,278 03/02/22
Polymeropoulos Mihael Hristos President and CEO President and CEO Feb 28 Sell 11.17 37,096 414,362 1,352,766 03/02/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Feb 28 Sell 11.24 12,305 138,308 119,691 03/02/22
Birznieks Gunther SVP, Business Develo.. SVP, Business Development Feb 28 Sell 11.23 15,601 175,199 188,807 03/02/22
Jones Aranthan II Chief Corp. Affairs.. Chief Corp. Affairs Officer Sep 17 Sell 16.49 16,824 277,428 81,980 09/17/21
Jones Aranthan II Chief Corp. Affairs.. Chief Corp. Affairs Officer Sep 17 Option 11.8 12,119 143,004 98,804 09/17/21
Williams Timothy SVP & General Counse.. SVP & General Counsel Mar 03 Sell 18.57 19,530 362,672 92,526 03/03/21
Watkins Thomas Director Director Feb 18 Option 7.11 15,000 106,650 55,323 02/18/21
Watkins Thomas Director Director Feb 18 Sell 18.54 5,818 107,866 49,505 02/18/21
DUGAN RICHARD W Director Director Feb 18 Option 7.11 15,000 106,650 60,641 02/18/21
DUGAN RICHARD W Director Director Feb 18 Sell 18.54 5,754 106,679 54,887 02/18/21